What happened?
On 17 August 2026, AstraZeneca and Daiichi Sankyo reported positive high-level results from DESTINY-Lung04, a global randomized open-label Phase III trial in 454 patients with unresectable, locally advanced or metastatic non-squamous NSCLC harbouring a HER2 exon 19 or 20 mutation. Enhertu (trastuzumab deruxtecan) produced a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review versus platinum-pemetrexed chemotherapy plus pembrolizumab. The trial continues for secondary endpoints including overall survival.
Why does it matter?
HER2 mutations occur in a small but actionable subgroup of NSCLC. Trastuzumab deruxtecan is already used after prior treatment in HER2-mutant metastatic NSCLC, so a positive first-line Phase III result could move HER2-directed therapy earlier in the treatment pathway if the full dataset, regulators and future guidelines support that use.
How to interpret the evidence
This is a topline company announcement, not yet a peer-reviewed full dataset. Numerical hazard ratios, median progression-free survival and mature overall-survival results were not provided in the announcement. The companies reported that the safety profile was generally consistent with the known profile and that no new safety concerns were identified; detailed efficacy and safety data are expected at a forthcoming medical meeting.
What remains uncertain?
It does not mean first-line approval has already been granted, and it should not change an individual patient’s treatment outside the relevant regulatory and specialist oncology context.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.